Risks and benefits of percutaneous biopsy and primary chemotherapy in advanced Wilms' tumour
| Autor: | P.G. Ransley, R.K. Marwaha, Patrick G. Duffy, Evelyn H. Dykes, V. Sams, R.A. Risdon, C. Dicks-Mireaux, J. Pritchard |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
medicine.medical_specialty Vincristine Percutaneous Adolescent medicine.medical_treatment Nephrectomy Wilms Tumor Biopsy Antineoplastic Combined Chemotherapy Protocols medicine Combined Modality Therapy Humans Child Survival rate Chemotherapy medicine.diagnostic_test business.industry Biopsy Needle Infant Wilms' tumor General Medicine medicine.disease Kidney Neoplasms Surgery Survival Rate Doxorubicin Child Preschool Pediatrics Perinatology and Child Health Dactinomycin Female Radiology business medicine.drug |
| Zdroj: | Journal of pediatric surgery. 26(5) |
| ISSN: | 0022-3468 |
| Popis: | Between 1982 and 1988, 36 children with advanced Wilms' tumour underwent percutaneous trucut needle biopsy followed by chemotherapy before definitive surgery. Nephrectomy was performed after a median of 14 weeks of chemotherapy. Substantial reduction in tumour bulk was achieved in 94% of patients. Biopsy morbidity was low and complete concordance between the histological assessment of the tumour in the biopsy specimen and at subsequent nephrectomy was confirmed in 26 of 28 (93%) patients. The overall clinical value of trucut biopsy was 83% (30/36 patients). Survival rates in this high-risk group were comparable to those of children with less advanced disease. Chemotherapy may be the primary treatment of choice for patients with Wilms' tumour. Percutaneous biopsy allows definition of histology in most patients without increasing morbidity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|